Loading…
B & B Pharmaceuticals, Inc. received an FDA Warning Letter on June 4, 2019, regarding drug manufacturing or marketing practices. While the specific violations are not detailed in the available metadata, the warning letter indicates regulatory concerns significant enough to warrant formal FDA enforcement action. The warning was issued under FDA's drug regulatory authority, though the specific issuing office and exact violation count are not documented in this summary. This summary is based on limited metadata and does not reflect the complete details contained in the full warning letter.